Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identi®cation of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to identify individuals at increased risk of developing the disease. It is probable that common genetic polymorphisms (variants) in genes directly and indirectly involved in androgen biosynthesis, metabolism and regulation are important. Other important genes are likely to be those directly involved in regulation of prostate cell proliferation and apoptosis. Prostate Cancer and Prostatic Diseases (2000) 3, 236±240.
Introduction
Prostate cancer is a pervasive disease, with an estimated 180 400 new cases in the US in 2000 (American Cancer Society). It is the most commonly diagnosed cancer in men, with estimates that one in six men will be diagnosed with prostate cancer over the course of a lifetime. Many risk factors have been suggested for prostate cancer, but for most, study results are inconsistent (see reviews by Nomura 1 and Ross 2 ). The only consistently reported risk factors are age, ethnicity and a family history. 3 In our aging population, research leading to a reduction in the incidence of and mortality from prostate cancer is an urgent necessity. A critical need in prostate cancer is to understand the risk factors involved in disease development and progression.
Prostate cancer is probably caused from complex interactions among genetic, endocrine and environmental factors. Genetic risk factors can include both rare genes that confer a high risk of developing disease to more common genes that confer a low to moderate risk. The possible role of inherited (germ-line) mutations in common genes in the etiology of prostate cancer is the focus of this review. Identi®cation of relevant genes that are important in the occurrence and/or progression of prostate cancer could be useful to design both preventative and therapeutic strategies, and to enable identi®ca-tion of individuals at increased risk of developing prostate cancer.
Common genes that may play a role in prostate cancer
Clinically important genetic risk factors that may result in differences in individual susceptibility to prostate cancer probably include genes directly involved in androgen biosynthesis, metabolism and regulation. Other likely genes include those involved in cell proliferation and apoptosis in the prostate, ie genes in the insulin-like growth factor system. The insulin-like growth factor system comprises insulin-like growth factors (IGFs), insulin-like growth factor binding proteins (IGFBPs), IGF proteases, and IGF-receptors. This system is important in prostate cell proliferation and apoptosis, both directly and indirectly through interacting with androgen regulation. 4 The role of steroid hormones in the etiology of prostate cancer is well documented. 5 ± 7 Prostate formation and growth is dependent on androgens that act through the androgen receptor to regulate gene expression. 8, 9 Henderson et al 10 hypothesized that prostate cancer risk is related to small contrasts in levels of androgens and estrogens that are within the normal endogenous range. Therefore, variation in genes that regulate hormonal levels may explain a proportion of prostate cancer risk. These genes are likely to be common and confer a low to moderate risk for prostate cancer. Contributory factors in the large racial/ethnic variation in the incidence of prostate cancer may be due to differences in serum testosterone levels 5 and 5a reductase activity. 11 Japanese men, with one of the lowest incidence of prostate cancer, have reduced activity of 5a reductase, 11 whereas African-American men, with the highest risk of prostate cancer in the world, have 10 ± 15% higher concentrations of circulating testosterone than their white counterparts. 5 The remainder of the differences could be due to other genes of diet and other lifestyle characteristics.
Genes involved in testosterone biosynthesis in the testes
In biosynthesis, cholesterol is converted to testosterone by a series of enzymatic reactions involving cholesterol side chain cleavage enzyme (CYP11a), 17a-hydroxylase (CYP17), 17-b hydroxysteroid dehydrogenase (HSD17B2), and 3b-hydroxysteroid dehydrogenase (HSD3B2). Testosterone then diffuses into the prostate cells (see Figure 1 ). Mutations and/or polymorphisms in any of these genes involved in testosterone synthesis could affect testosterone levels in the prostate. Genetic polymorphisms in CYP11a, CYP17, HSD3B2, and HSD17B2 have all been reported. 12 ± 16 CYP11a alleles are strongly associated with total serum testosterone levels. 15 A CYP17 A2 variant has been associated with an increased risk of prostate cancer, with an odds ratio of 1.7. 17 
Genes involved in androgen metabolism and regulation in the prostate
In the prostate, approximately 90% of testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5a reductase type 2 (SRD5A2). 6 Testosterone is deactivated by 17b-hydroxysteroid dehydrogenase type II (HSD17B2) to androstenedione 7 or by nifedipine oxidase (CYP3A4) to 2b-, 6b-or 15b hydroxytestosterone. 18 DHT, the active intracellular androgen in prostate cells, activates the androgen receptor (AR), that then interacts with target genes. 19 DHT is deactivated by either 3a-or 3b-hydroxysteroid dehydrogenase type II (HSD3B2) to 5a-androstane-3a, 17b-diol (3a-adiol) 7 (see Figure 2) .
Polymorphisms in CYP3A4, SRD5A2, HSD3B2 and AR have all been reported. 20 ± 24 There are differences in frequencies of alleles among African-Americans, Caucasians, and Asians for SRD5A2, 17,22,25 HSD3B2 13 and AR. 20, 21 These differences are suggestive that these genes may explain a proportion of ethnic differences in prostate cancer risk and therefore be important in the etiology of prostate cancer. Functional differences in level of activity of genetic variants have been reported for SRD5A2 22, 24 and AR. 9 These functional differences could be associated with prostate cancer risk. For example, increased transactivation from short AR variants could cause chronic androgen overstimulation in the prostate and therefore a higher risk for cancer, whereas reduced androgen responsiveness from long AR variants could be protective to the prostate. 26 There have been several studies examining the risk of prostate cancer with variants in some of these genes. For the AR CAG repeats, there was a signi®cantly increased risk associated with a decreased number of repeats in two studies, 21,27 a trend towards a 3% decrease in risk of prostate cancer for each additional CAG repeat in a third study, 28 and no association in a fourth study. 29 For SRD5A2, the A49T variant has been associated with prostate cancer in Hispanics and African-Americans. 30 Jaffe et al 31 reported an association of the A49T variant with pathological stage. The SRD5A2 V89L variant was not associated with serum androstanediol glucuronide levels, 32 nor with risk of prostate cancer. 17, 31, 32 For CYP3A4, which deactivates testosterone, a variant has been identi®ed which has altered testosterone metabolism. 33, 34 This variant has the highest frequency in African-Americans, mid-frequency in Caucasians, and lowest frequency in Asians, 35, 36 re¯ecting relative prostate cancer rates in these populations. The CYP3A4 variant was associated with prostate cancer risk in Caucasians 23 and African-Americans 36 in case ± control studies.
Other genes involved in androgen regulation and cell proliferation and apoptosis in the prostate Androgens are involved in regulation of cell proliferation in the prostate. However, other factors must also be involved. The IGF system may be an important pathway, as it is involved in prostate cell proliferation and apoptosis, both through interaction with androgens and independently. The roles of these various genes are shown in Figure 2 .
Insulin is a potent mitogen in cells, including the prostate. It indirectly regulates levels of available insulin-like growth factor-1 (IGF-1) through down-regulating 
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IGFBPs. It directly regulates levels of sex hormone binding globulin (SHBG). When insulin levels decrease, SHBG levels increase. 37 SHBG binds to testosterone and estradiol, and therefore regulates the biologically available levels of these hormones. 38 Higher levels of SHBG would reduce the level of bioavailable testosterone, and consequently be protective against the development of prostate cancer. 39 This corresponds to the report of Gann et al 40 in which high levels of circulating testosterone and low levels of SHBG, both within the normal range, were risk factors for prostate cancer. The lower risk of prostate cancer among diabetics may be partially explained by the role of insulin in indirectly affecting levels of IGF-1 and directly affecting SHBG levels. 41 IGF-1, involved in the regulation of cell growth and differentiation in prostate cells, is a mitogen whereby increased bioavailability results in increased cell proliferation. 41 ± 43 One mechanism by which IGF-1 regulates cell growth may be by modulating levels of DHT in the prostate. IGF-1 increases activity of SRD5A2 in a dosedependent matter, therefore modulating the level of DHT. 41 Both insulin-like growth factor binding protein-1 (IGFBP-1) and insulin-like growth factor binding protein-3 (IGFBP-3) may be important in prostate cancer risk, largely through binding of IGF-1. Although 95% of IGF-1 is bound to IGFBP-3, 44 the IGF-1/IGFBP-3/ALS complex is too large to pass through blood vessel endothelial cells and affect target tissue. 45 IGFBP-1 shuttles IGF-1 to target tissues, so that levels of IGFBP-1 could be important in determining the amount of IGF-1 available in prostate tissue. In the prostate, IGFBP-3 binds to IGF-1 so that a decrease in IGFBP-3 could result in increased bioavailability of IGF-1. 46 Independent of IGF-1, IGFBP-3 has direct inhibitory effects on cell growth by facilitating apopotosis. 47, 48 Finally, the active vitamin D metabolite, 1,25(OH)D3 inhibits prostate cell proliferation, and levels are mediated by the vitamin D receptor (VDR). 49 ± 51 Low serum levels of 1,25(OH)D3 have been reported in prostate cancer. 52, 53 Increased levels of 1,25(OH)D3 increase IGFBP-3. 52, 53 Increased IGFBP-3 results in increased apoptosis and decreased IGF-1 bioavailability, which would decrease SRD5A2 levels, leading to a decrease in DHT.
Polymorphisms in IGF-1, SHBG and VDR 42,54 ± 58 and functional differences in level of activity of variants in these genes 56, 58, 59 have been reported. These functional differences may be associated with prostate cancer risk. For VDR, three of ®ve studies reported signi®cant associations of VDR polymorphisms with prostate cancer risk. 27,60 ± 63 Genetic variants of IGF-1, IGFBP-1 and IGFBP- 3 have not yet been investigated. However, signi®cant associations of serum levels with prostate cancer risk have been reported. In three of four studies, elevated IGF-1 serum levels were associated with increased prostate cancer risk. 64 ± 68 In a case ± control study, elevated IGFBP-1 serum levels were associated with an odds ratio of 5 for developing prostate cancer. 69 For IGFBP-3, plasma levels of IGFBP-3 are lower among African-Americans than Caucasians and Asians, and lower levels been suggested as a contributory factor in the higher rate of prostate cancer in African-Americans. 70, 71 Examination of genetic variants of these proteins is needed as it will be independent of factors that affect IGF serum level measurements.
Conclusions
Prostate cancer is likely caused from complex interactions among genetic, endocrine and environmental factors. Ethnic differences in risk suggest that in addition to environmental factors, common genetic variants with low penetrance and high population attributable risk Figure 2 Simplistic working model of interrelationships of genes in the insulin-like growth factor pathway and the androgen pathway, with cell proliferation and apoptosis.
Genetic epidemiology of prostate cancer SL Neuhausen may play an essential role in the etiology of prostate cancer. In this review, we have described genes involved in the androgen and the insulin-like growth factor pathways that could confer an increased risk for development and progression of prostate cancer through their mediation of prostate cell proliferation and apoptosis. These low penetrance genes may act alone or may be in response to environmental or lifestyle triggers, ie smoking, high-fat diets. It may be that gene ± gene and gene ± environment interactions are important and these interactions need to be explored. The genes discussed here are not inclusive, and there are many other genes that may be important, ie genes involved in DNA repair or in carcinogen metabolism. For example, the phase I enzymes such as the cytochrome P450s (eg CYP2E1, CYP1A1, and CYP2D6) and NAD(P)II: quinone oxidoreductase (NQO1) convert substrates into reactive intermediates that are then detoxi®ed by phase II enzymes, including glutathione S-transferases (eg GSTP1, GSTM1 and GSTT1). 72 Thus, variants in these genes may be important in cancer risk, and speci®cally prostate cancer risk.
Inconsistent results among studies are often reported for association studies. These inconsistencies may be due to different experimental designs, sample sizes, ethnic groups, and/or phenotypes examined. Because these genes probably confer only a small risk for developing cancer, large cohorts and case ± control populations are required in order to assess their signi®cance. Investigations of low penetrance genes may be critical to understanding the increased incidence of prostate cancer, and may yield new comprehension of the mechanisms and control of this common disease.
